Table 5.12.2Treatment response in randomized controlled trials of mandibular advancement devices vs. CPAP

Study
PMID
Baseline AHI (SD) [eligibility]Baseline ESS (SD)Duration (design)Outcome (subgroup)Interventionsn EventN TotalMetricResult *95% CIP BtwDropout, %Study Quality
Hoekema 2008230
18719218
40 (28) [≥5]14.2 (5.6)78 d [IQR 60–88 d] (PL)Effective Treatment (Total)MAD3951RD−6.2%−22, 9.4NS4B
CPAP4352
(AHI≤30)MAD2125RD+4.0%−18, 25NS
CPAP2025
(AHI>30)MAD1826RD−1.6%−37, 6.8NS
CPAP2327
AHI<5 (Total)MAD2951RD−20.0%−37, −1.90.02
CPAP4052
(AHI≤30)MAD2125RD+4.0%−18, 25NS
CPAP2025
(AHI>30)MAD826RD−43.3%−62, −17<0.001 §
CPAP2027
AHI<10 ** (Total)MAD3144RD−4.5%−23, 14NS
CPAP3344
(AHI≤30)MAD1618RD+18.3%−8.7, 43NS
CPAP1217
(AHI>30)MAD1526RD−20.1%−42, 4.9NS
CPAP2127
Gagnadoux 2009227
19324954
34 (13) [10–60]10.6 (4.5)2 mo (XO)Complete Response ††MAD1228RD ‡‡−28.6%−53, −3.80.02 §§0B
CPAP2028
Partial *** or Complete ResponseMAD2628RD †††−3.6%−15, 8.2NS ‡‡‡
CPAP2728
*

Top row intervention vs. bottom row intervention.

AHI<5 or >50% reduction to an AHI<20 without symptoms

Estimated from confidence interval

§

Estimated from confidence interval

**

Excluding 15 participants who had AHI<10 at baseline.

††

≥50% reduction in AHI to <5

‡‡

Calculated from reported data

§§

Calculated from reported data

***

≥50% reduction in AHI to ≥5

†††

Calculated from reported data

‡‡‡

Calculated from reported data

From: Appendix D, Summary Tables

Cover of Diagnosis and Treatment of Obstructive Sleep Apnea in Adults
Diagnosis and Treatment of Obstructive Sleep Apnea in Adults [Internet].
Comparative Effectiveness Reviews, No. 32.
Balk EM, Moorthy D, Obadan NO, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.